CLLS Stock Summary and Trading Ideas (Cellectis S.A. - American Depositary Shares | NASDAQ:CLLS)

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol CLLS.

As of February 20, 2026, CLLS stock price declined to $3.90 with 10,396 million shares trading.

CLLS has a beta of 0.89, meaning it tends to be less sensitive to market movements. CLLS has a correlation of 0.04 to the broad based SPY ETF.

CLLS has a market cap of $392.30 million. This is considered a Small Cap stock.

Last quarter Cellectis S.A. - American Depositary Shares reported $37 million in Revenue and $.02 earnings per share. This beat revenue expectation by $29 million and exceeded earnings estimates by $.12.

In the last 3 years, CLLS traded as high as $5.48 and as low as $.96.

The top ETF exchange traded funds that CLLS belongs to (by Net Assets): IBB.

CLLS has outperformed the market in the last year with a price return of +153.2% while the SPY ETF gained +14.1%. However, in the short term, CLLS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -18.4% vs +6.0% return in SPY. But in the last 2 weeks, CLLS shares have fared better than the market returning +9.2% compared to SPY -0.2%.

CLLS support price is $3.76 and resistance is $4.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLLS shares will trade within this expected range on the day.